<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486902</url>
  </required_header>
  <id_info>
    <org_study_id>0524-030</org_study_id>
    <nct_id>NCT00486902</nct_id>
  </id_info>
  <brief_title>Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?</brief_title>
  <official_title>Does a Single Intravenous Dose of Ketamine Reduce the Need for Supplemental Opioids in Post-Cesarean Section Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain control after cesarean delivery is associated with improved breastfeeding and infant
      rooming-in times. In addition, inadequate analgesia leads to elevated plasma catecholamine
      concentrations, which negatively affect every organ system. There is growing evidence that
      ketamine, N-methyl-D-aspartate receptor antagonist, is efficacious when used as an adjuvant
      in postoperative pain control. A 2006 Cochrane Collaboration systemic review and
      meta-analysis concluded, &quot;Ketamine in subanesthetic doses….is effective in reducing morphine
      requirements in the first 24 hours after surgery.&quot;

      Ketamine's prolonged analgesic effect, despite its short half-life and its use in low doses,
      is theorized to be due to blockade of spinal cord central sensitization. Central
      sensitization is a phenomenon whereby repeated painful stimulus leads to more severe pain
      perception over time despite no change in the intensity of the painful stimulus.Ketamine may
      also prevent the development of acute opioid tolerance. Ketamine's analgesic effects have
      also demonstrated in the obstetric population. Post-cesarean delivery morphine requirements
      in women who received ketamine as part of a general anesthesia technique were decreased.
      Similary, low-dose ketamine in conjunction with bupivacaine-only spinal anesthesia reduced
      postoperative analgesic requirements compared to bupivacaine-only spinal anesthesia and
      bupivacaine-fentanyl spinal anesthesia.

      In the United States, healthy women scheduled for elective cesarean delivery commonly receive
      spinal anesthesia with bupivacaine-fentanyl-morphine. To our knowledge, IV ketamine has not
      been studied as an adjuvant to this regimen in the analgesic management in post-cesarean
      delivery patients. Multimodal therapy for postoperative pain control is widely practiced due
      to the advantage it provides in blocking multiple pain pathways while minimizing side effects
      of each individual pain medication. We hypothesize that low dose intravenous ketamine will
      improve multi-modal post-cesarean analgesia compared to placebo. The purpose of this study is
      to evaluate this hypothesis and study the possible side effects of this regimen in
      combination with bupivacaine-fentanyl-morphine spinal anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women for elective cesarean section admitted to the Labor and Delivery Unit of
      Prentice Women's Hospital will be approached for study participation immediately after the
      routine preanesthetic evaluation. This occurs shortly after admission to the Labor and
      Delivery Unit. Women who agree to participate will give written, informed consent at this
      time.

      Subjects will be prepared preoperatively in the usual fashion with intravenous (IV) access,
      aspiration prophylaxis and intraoperative monitoring. Preincision antibiotics will be given
      and uterotonic medications will be used as per usual practice after delivery.

      The anesthesiologist will perform a spinal anesthetic per routine with the subject in the
      sitting position using sterile technique at the L3-4 interspace (± one vertebral interspace).
      The spinal anesthetic will consist of 12 mg of hyperbaric bupivacaine + 15 μg fentanyl + 150
      μg of morphine. The subject will be placed supine with left lateral tilt to alleviate
      aortocaval compression. Cesarean section will commence after adequate anesthesia is assured
      to a T4 sensory level to pinprick. Vasopressors and IV fluids will be administered at the
      anesthesiologist's discretion per usual practice.

      At the time of delivery, subjects will be randomized to one of two groups using a computer
      generated random number table. Randomization will be blocked based on whether the cesarean
      procedure is a primary or a repeat procedure. Randomization assignments will be kept in
      sequentially numbered opaque envelopes. The envelope will be opened by a research nurse who
      will prepare a 20 mL syringe labeled &quot;study drug&quot;. The syringe will be given to the
      anesthesiologist blinded to the treatment group who will subsequently administer the study
      drug. Subjects randomized to the treatment group will receive ketamine 10 mg (ketamine 10
      mg/mL) diluted to 20 mL with 0.9% preservative free saline. Subjects randomized to the
      placebo group will receive 20 mL preservative free saline.

      The study drug will be administered into the intravenous line via an infusion pump over 10
      minutes. Five minutes after placebo or drug administration, the anesthesiologist will ask the
      subject if she has nausea, vomiting and pruritus. Nausea and pruritus will be graded as none,
      mild, moderate or severe; and vomiting as present or absent. Any spontaneous complaints of
      psychedelic effects will be noted at this time. Sedation will be assessed via the Richmond
      agitation-sedation scale (RASS [see Appendix 1]).

      Upon completion of the cesarean section, the subject will be transported to the post
      anesthesia recovery unit. Patients will receive ketorolac 30 mg every 6 hours time 4 doses
      beginning shortly after admission to the PACU.

      At 1 h, 4 h, 8 h, 12 h and at 24 h after administration of the study drug, the subject's pain
      will be assessed using the numeric rating scale for pain NRS 0-10 (see Appendix 2). Patients
      may request rescue analgesia if they are experiencing discomfort. The time of first rescue
      analgesia request will be noted, and the NRS will be determined at the time of request for
      rescue analgesia.

      Rescue medication will consist of hydrocodone 10 mg plus acetaminophen 325 mg per os. An
      additional dose of hydrocodone 10 mg plus acetaminophen 325 mg will be provided after 1 hour
      if the pain is not relieved to the subject's satisfaction. These are routine oral analgesic
      medications for postoperative cesarean delivery analgesia. Standard orders will be written
      for monitoring sedation and respiratory rate, and treatment of side effects (nausea,
      vomiting, pruritus and respiratory depression). The total amount of rescue medication will be
      determined for each subject after 24, 48 and 72 hours.

      The presence of nausea, vomiting, and pruritus will be assessed at the same time intervals as
      the NRS for pain: 1 h, 4 h, 8 h, 12 h and 24 h after IV infusion of ketamine or placebo. The
      subjective psychedelic effects of ketamine and morphine will be assessed using a set of
      true/false questions from the LSD and morphine short form of the Addiction Research Center
      Inventory, ARCI (Appendix 3). These questions will be administered verbally by the
      anesthesiologist or researcher blinded to the treatment group upon admission to the PACU and
      at 4 h.

      The following data will be collected in addition to the primary and secondary outcome data:
      maternal age, height, weight, prepregnancy weight, gestational age and IV fluids administered
      during cesarean section. In addition, all intraoperative and postoperative medications will
      be recorded, including those administered for the treatment of side effects listed above.

      Protocol specific analgesia assessment ends 24 hours after administration of the study drug.
      At 72 hours the subject will be asked about her satisfaction with postoperative analgesia
      (100 mm scale, 0 mm = not satisfied at all, 100 mm = very satisfied). One telephone follow-up
      evaluation 2 weeks after delivery will again, assess for satisfaction with analgesia and
      average pain (NRS) since the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Requiring Supplemental Analgesia in the First 24 Hours Following Cesarean Delivery</measure>
    <time_frame>24 hours</time_frame>
    <description>Request for oral hydrocodone/acetaminophen for pain not controlled by around the clock non-steroidal antiflammatory drugs in the first 24 hours following cesarean delivery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verbal Pain Scores (0 to 10) at First Analgesia Request</measure>
    <time_frame>24 hours</time_frame>
    <description>Numeric rating of pain scores (NRS) scale (0 to 10) at time of supplemental analgesia request. Zero is no pain and 10 is worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Hydrocodone/Acetaminophen for Supplemental Analgesia to Treat Breakthrough Pain</measure>
    <time_frame>72 hours</time_frame>
    <description>Cumulative hydrocodone/acetaminophen for supplemental analgesia to treat breakthrough pain for 72 hours following cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of subjects reporting nausea in first 24 hours following cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of subjects that vomited in the first 24 hours following cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postperative Pruritus</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of subjects with pruritus in the first 24 hours following cesarean delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disturbing Dreams</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of subject reporting disturbing dreams at 72 hours post cesarean delivery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">188</enrollment>
  <condition>Ketamine Adverse Reaction</condition>
  <condition>Effects of; Anesthesia, Spinal and Epidural, in Pregnancy</condition>
  <condition>Complication of Labor and/or Delivery</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute</description>
    <arm_group_label>Ketamine</arm_group_label>
    <other_name>N-methyl-D-aspartate (NMDA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible women are at term (≥37 week gestation),

          -  Healthy,

          -  ASA class 1-2,

          -  Scheduled for elective cesarean section whose anesthetic plan is for spinal anesthesia
             with intrathecal morphine and intravenous ketorolac analgesia for post operative
             analgesia

        Exclusion Criteria:

          -  Women with American Society of Anesthesiologists physical status &gt;2,

          -  Body mass index ≥40 kg/m2,

          -  Known allergy to any of the study medications,

          -  Contraindication to the spinal anesthesia,

          -  History of substance abuse,

          -  History of hallucinations,

          -  Chronic opioid therapy,

          -  Chronic pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia A Wong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yost NP, Bloom SL, Sibley MK, Lo JY, McIntire DD, Leveno KJ. A hospital-sponsored quality improvement study of pain management after cesarean delivery. Am J Obstet Gynecol. 2004 May;190(5):1341-6.</citation>
    <PMID>15167840</PMID>
  </reference>
  <reference>
    <citation>Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth Analg. 2004 Aug;99(2):482-95, table of contents. Review.</citation>
    <PMID>15271729</PMID>
  </reference>
  <reference>
    <citation>Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004603. Review. Update in: Cochrane Database Syst Rev. 2015;7:CD004603.</citation>
    <PMID>16437490</PMID>
  </reference>
  <reference>
    <citation>Menigaux C, Fletcher D, Dupont X, Guignard B, Guirimand F, Chauvin M. The benefits of intraoperative small-dose ketamine on postoperative pain after anterior cruciate ligament repair. Anesth Analg. 2000 Jan;90(1):129-35.</citation>
    <PMID>10624993</PMID>
  </reference>
  <reference>
    <citation>Menigaux C, Guignard B, Fletcher D, Sessler DI, Dupont X, Chauvin M. Intraoperative small-dose ketamine enhances analgesia after outpatient knee arthroscopy. Anesth Analg. 2001 Sep;93(3):606-12.</citation>
    <PMID>11524327</PMID>
  </reference>
  <reference>
    <citation>Kwok RF, Lim J, Chan MT, Gin T, Chiu WK. Preoperative ketamine improves postoperative analgesia after gynecologic laparoscopic surgery. Anesth Analg. 2004 Apr;98(4):1044-9, table of contents.</citation>
    <PMID>15041596</PMID>
  </reference>
  <reference>
    <citation>Argiriadou H, Himmelseher S, Papagiannopoulou P, Georgiou M, Kanakoudis F, Giala M, Kochs E. Improvement of pain treatment after major abdominal surgery by intravenous S+-ketamine. Anesth Analg. 2004 May;98(5):1413-8, table of contents.</citation>
    <PMID>15105223</PMID>
  </reference>
  <reference>
    <citation>Guillou N, Tanguy M, Seguin P, Branger B, Campion JP, Mallédant Y. The effects of small-dose ketamine on morphine consumption in surgical intensive care unit patients after major abdominal surgery. Anesth Analg. 2003 Sep;97(3):843-7.</citation>
    <PMID>12933413</PMID>
  </reference>
  <reference>
    <citation>Guignard B, Coste C, Costes H, Sessler DI, Lebrault C, Morris W, Simonnet G, Chauvin M. Supplementing desflurane-remifentanil anesthesia with small-dose ketamine reduces perioperative opioid analgesic requirements. Anesth Analg. 2002 Jul;95(1):103-8, table of contents.</citation>
    <PMID>12088951</PMID>
  </reference>
  <reference>
    <citation>Xie H, Wang X, Liu G, Wang G. Analgesic effects and pharmacokinetics of a low dose of ketamine preoperatively administered epidurally or intravenously. Clin J Pain. 2003 Sep-Oct;19(5):317-22.</citation>
    <PMID>12966258</PMID>
  </reference>
  <reference>
    <citation>Suzuki M, Tsueda K, Lansing PS, Tolan MM, Fuhrman TM, Ignacio CI, Sheppard RA. Small-dose ketamine enhances morphine-induced analgesia after outpatient surgery. Anesth Analg. 1999 Jul;89(1):98-103.</citation>
    <PMID>10389785</PMID>
  </reference>
  <reference>
    <citation>Aida S, Yamakura T, Baba H, Taga K, Fukuda S, Shimoji K. Preemptive analgesia by intravenous low-dose ketamine and epidural morphine in gastrectomy: a randomized double-blind study. Anesthesiology. 2000 Jun;92(6):1624-30.</citation>
    <PMID>10839912</PMID>
  </reference>
  <reference>
    <citation>Kararmaz A, Kaya S, Karaman H, Turhanoglu S, Ozyilmaz MA. Intraoperative intravenous ketamine in combination with epidural analgesia: postoperative analgesia after renal surgery. Anesth Analg. 2003 Oct;97(4):1092-6, table of contents.</citation>
    <PMID>14500163</PMID>
  </reference>
  <reference>
    <citation>Ilkjaer S, Nikolajsen L, Hansen TM, Wernberg M, Brennum J, Dahl JB. Effect of i.v. ketamine in combination with epidural bupivacaine or epidural morphine on postoperative pain and wound tenderness after renal surgery. Br J Anaesth. 1998 Nov;81(5):707-12.</citation>
    <PMID>10193280</PMID>
  </reference>
  <reference>
    <citation>Woolf CJ, Chong MS. Preemptive analgesia--treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993 Aug;77(2):362-79. Review.</citation>
    <PMID>8346839</PMID>
  </reference>
  <reference>
    <citation>Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 1995 Sep;62(3):259-74. Review.</citation>
    <PMID>8657426</PMID>
  </reference>
  <reference>
    <citation>Ngan Kee WD, Khaw KS, Ma ML, Mainland PA, Gin T. Postoperative analgesic requirement after cesarean section: a comparison of anesthetic induction with ketamine or thiopental. Anesth Analg. 1997 Dec;85(6):1294-8.</citation>
    <PMID>9390597</PMID>
  </reference>
  <reference>
    <citation>Kashefi P. The benefits of intraoperative small-dose ketamine on postoperative pain after cesarean section. Anesthesiology 2006;104, Supp 1.</citation>
  </reference>
  <reference>
    <citation>Sen S, Ozmert G, Aydin ON, Baran N, Caliskan E. The persisting analgesic effect of low-dose intravenous ketamine after spinal anaesthesia for caesarean section. Eur J Anaesthesiol. 2005 Jul;22(7):518-23.</citation>
    <PMID>16045141</PMID>
  </reference>
  <reference>
    <citation>Downing JW, Mahomedy MC, Jeal DE, Allen PJ. Anaesthesia for Caesarean section with ketamine. Anaesthesia. 1976 Sep;31(7):883-92.</citation>
    <PMID>9839</PMID>
  </reference>
  <reference>
    <citation>Dich-Nielsen J, Holasek J. Ketamine as induction agent for caesarean section. Acta Anaesthesiol Scand. 1982 Apr;26(2):139-42.</citation>
    <PMID>7102236</PMID>
  </reference>
  <reference>
    <citation>Maduska AL, Hajghassemali M. Arterial blood gases in mothers and infants during ketamine anesthesia for vaginal delivery. Anesth Analg. 1978 Jan-Feb;57(1):121-3.</citation>
    <PMID>24371</PMID>
  </reference>
  <reference>
    <citation>Bar-Oz B, Bulkowstein M, Benyamini L, Greenberg R, Soriano I, Zimmerman D, Bortnik O, Berkovitch M. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 2003;26(13):925-35. Review.</citation>
    <PMID>14583068</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2007</study_first_posted>
  <results_first_submitted>March 15, 2011</results_first_submitted>
  <results_first_submitted_qc>April 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2011</results_first_posted>
  <last_update_submitted>March 17, 2014</last_update_submitted>
  <last_update_submitted_qc>March 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Cynthia Wong</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Spinal Anesthesia</keyword>
  <keyword>C-section</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obstetric Labor Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>N-Methylaspartate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at Prentice Women's Hospital between August 2006 and November 2006.</recruitment_details>
      <pre_assignment_details>188 subjects were recruited for the study. 5 subjects in the ketamine group and 3 in the saline group were excluded after randomization but before study drug administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>decision for postpartum tubal ligation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>spinal anesthetic protocal violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No toradol due to hemmorhage or allergy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="3"/>
                    <measurement group_id="B2" value="34" spread="3"/>
                    <measurement group_id="B3" value="34" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Requiring Supplemental Analgesia in the First 24 Hours Following Cesarean Delivery</title>
        <description>Request for oral hydrocodone/acetaminophen for pain not controlled by around the clock non-steroidal antiflammatory drugs in the first 24 hours following cesarean delivery.</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was performed per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Requiring Supplemental Analgesia in the First 24 Hours Following Cesarean Delivery</title>
          <description>Request for oral hydrocodone/acetaminophen for pain not controlled by around the clock non-steroidal antiflammatory drugs in the first 24 hours following cesarean delivery.</description>
          <population>Analysis was performed per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size was determined assuming an incidence of breakthrough pain of 75% and an absolute difference between groups of -20 to +15%. This rate of request for analgesia in the first 24 h was based on data from a parallel study utilizing the same multimodal postoperative pain regimen for cesarean delivery. Group sample sizes of 90 achieve 80% power to detect this difference using the two-sided Z test with pooled variance. The significance level of the test was targeted at 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal Pain Scores (0 to 10) at First Analgesia Request</title>
        <description>Numeric rating of pain scores (NRS) scale (0 to 10) at time of supplemental analgesia request. Zero is no pain and 10 is worst pain imaginable.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Scores (0 to 10) at First Analgesia Request</title>
          <description>Numeric rating of pain scores (NRS) scale (0 to 10) at time of supplemental analgesia request. Zero is no pain and 10 is worst pain imaginable.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Hydrocodone/Acetaminophen for Supplemental Analgesia to Treat Breakthrough Pain</title>
        <description>Cumulative hydrocodone/acetaminophen for supplemental analgesia to treat breakthrough pain for 72 hours following cesarean delivery</description>
        <time_frame>72 hours</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Hydrocodone/Acetaminophen for Supplemental Analgesia to Treat Breakthrough Pain</title>
          <description>Cumulative hydrocodone/acetaminophen for supplemental analgesia to treat breakthrough pain for 72 hours following cesarean delivery</description>
          <population>Analysis was per protocol</population>
          <units>tablets</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="14"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Nausea</title>
        <description>Number of subjects reporting nausea in first 24 hours following cesarean delivery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea</title>
          <description>Number of subjects reporting nausea in first 24 hours following cesarean delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Vomiting</title>
        <description>Number of subjects that vomited in the first 24 hours following cesarean delivery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Vomiting</title>
          <description>Number of subjects that vomited in the first 24 hours following cesarean delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postperative Pruritus</title>
        <description>Number of subjects with pruritus in the first 24 hours following cesarean delivery</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Postperative Pruritus</title>
          <description>Number of subjects with pruritus in the first 24 hours following cesarean delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disturbing Dreams</title>
        <description>Number of subject reporting disturbing dreams at 72 hours post cesarean delivery</description>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Disturbing Dreams</title>
          <description>Number of subject reporting disturbing dreams at 72 hours post cesarean delivery</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Pain Score (0-10) at 2 Weeks Following Cesarean Delivery</title>
        <description>Numeric rating for pain score (0 to 10) reported at 2 weeks following cesarean delivery. Zero is no pain and 10 is worst pain imaginable.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score (0-10) at 2 Weeks Following Cesarean Delivery</title>
          <description>Numeric rating for pain score (0 to 10) reported at 2 weeks following cesarean delivery. Zero is no pain and 10 is worst pain imaginable.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects receive IV Saline 20 mL 5 minutes after infant delivery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.01</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Spontaneous complaint of psycho-mimetic reaction</sub_title>
                <description>Spontaneous complaint of psycho-mimetic reaction (feeling clumsy or weird feeling) reported by subject 5 minutes after administration of study drug.</description>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="85"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="89"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert J. McCarthy</name_or_title>
      <organization>Northwestern University Feinberg School of Medicine</organization>
      <phone>312-926-9015</phone>
      <email>r-mccarthy@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

